newsit

Get Ready to Invest: Kalera Public Limited Company Sets the Stage for a Successful Public Offering of $8.84 Million!

Welcome to the Jungle: Kalera’s Wild Ride Let’s Talk About Money, Honey! So, did you hear the latest news from Kalera Public Limited Company? They just announced the pricing of their $8.84 million public offering! Talk about making it rain, right? As a company that specializes in vertical farming, they’re definitely planting the seeds for…

Read More

Discover the Latest in Cancer Research: Rain Therapeutics to Present at Prestigious EORTC-AACR-NCI Symposium

Rain Therapeutics: Advancing Precision Oncology Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium NEWARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53,…

Read More

Level Up Your Cybersecurity Skills: Kaspersky Unveils Innovative Online Training for Mobile Malware Reverse Engineering Experts

Kaspersky launches a new online cybersecurity training for ‘Mobile Malware Reverse Engineering’ experts Woburn, MA, Oct. 26, 2022 (GLOBE NEWSWIRE) Developed by Kaspersky experts, the company’s new ‘Mobile Malware Reverse Engineering’ course helps upgrade any security team’s ability to counter various cyber threats caused for business by smartphones. The new learning program helps to develop…

Read More

Kura Oncology’s Groundbreaking Findings: Tipifarnib and Alpelisib Combination Shows Promise in Treating Head and Neck Squamous Cell Carcinoma – A Preliminary Report from Phase 1/2 Clinical Trial

Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpe… First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC Preclinical data support potential to address ~45% of HNSCC tumors that harbor HRAS overexpression and/or PIK3CA mutation SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE)…

Read More

Attention Enviva Inc. Investors: Don’t Miss Out on Potential Compensation! Respected Investor Counsel Urges You to Inquire About Securities Class Action Investigation for EVA Losses

Welcome to the Jungle: Navigating Securities Claims with Rosen Law Firm Oct. 19, 2022: A Globe Newsflash! Strap in, folks! Prepare for a wild ride as we delve into the latest buzz surrounding Enviva Inc. (NYSE: EVA) and the investigations underway by the esteemed Rosen Law Firm. Hold on to your hats! Picture this: you’re…

Read More

Former Louisiana Attorney General Sounds Alarm for PayPal Shareholders: Important Deadline Approaching in Class Action Lawsuit

PAYPAL Shareholder Alert: KSF Reminds Investors to File Lead Plaintiff Applications NEW ORLEANS, Oct. 18, 2022 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 5, 2022 to file lead plaintiff applications in a securities class…

Read More

Unveiling the Success Story: Equity Bancshares Inc. Reports Impressive Third Quarter Results with Continued Organic Growth

Equity Bancshares, Inc. Reports Third Quarter Results, Continued Organic Growth Company saw 3.5% linked quarter revenue growth Equity Bancshares, Inc. recently announced their third quarter results, showing a 3.5% linked quarter revenue growth. This growth has been attributed to expanding Net Interest Margin, showcasing the company’s strong financial performance and strategic management. 19.7% reduction in…

Read More